

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

NCT04464122

Status RECRUITING
Sponsor University of Roma La Sapienza
Enrollment 60 participants

Key Eligibility Criteria

Inclusion (2)

- Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
- Patients affected by other non-malignant endocrine disease, e.g. benign thyroid dysfunction (control group).

Exclusion (3)

- Severe chronic kidney disease (stage 4-5);
- Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
- Other non-neuroendocrine malignancies.

Locations (1 total)

Andrea M Isidori, Rome, Italy, Italy